Skip to content
Subscribe Follow on LinkedIn

Latest

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

✨ Onyx Summary Lexicon Pharmaceuticals announced new data from the SOTA P CARDIA trial presented at AHA 2025 showing that sotagliflozin significantly improved cardiac structure, diastolic function, exercise capacity, and quality of life in heart failure patients with preserved ejection fraction and without diabetes. The findings, led by Mount Sinai’s

Guardant Health to Participate in Upcoming Investor Conferences

Guardant Health to Participate in Upcoming Investor Conferences

✨ Onyx Summary Guardant Health announced its participation in two upcoming investor conferences: the Jefferies Global Healthcare Conference in London on November 19 and the Piper Sandler 37th Annual Healthcare Conference in New York on December 2. Live and archived webcasts of both fireside chats will be available on the company’

enGene to Participate in Upcoming Investor Conferences

enGene to Participate in Upcoming Investor Conferences

✨ Onyx Summary enGene Holdings announced that management will participate in three upcoming investor conferences—the Guggenheim Healthcare Innovation, Stifel 2025 Healthcare, and Jefferies Global Healthcare Conferences—throughout November 2025. Webcasts of the presentations will be available on the company’s investor website for 90 days. BOSTON & MONTREAL – enGene Holdings

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

✨ Onyx Summary Guardant Health granted restricted stock units representing 184,961 shares and one stock option for 5,731 shares to new non-executive employees under its 2023 Employment Inducement Incentive Award Plan, with an exercise price of $93.02 per share. The awards, approved on October 21, 2025, serve as

Seer Reports Third Quarter 2025 Financial Results

Seer Reports Third Quarter 2025 Financial Results

✨ Onyx Summary Seer reported third-quarter 2025 revenue of $4.1 million, up 2% year-over-year, with a net loss of $18.2 million and $251.2 million in cash and investments. The company saw record adoption of its Proteograph ONE workflow and a surge in third-party publications, underscoring expanding market validation

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

✨ Onyx Summary Recursion reported a third-quarter 2025 net loss of $162.3 million on $5.2 million in revenue, with $667 million in cash and an expected runway through 2027. The company achieved over $500 million in cumulative upfront and milestone payments from partners Roche, Genentech, and Sanofi, advanced multiple

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

✨ Onyx Summary Recursion announced a leadership transition effective January 1, 2026, with Chief R&D and Commercial Officer Najat Khan, Ph.D., appointed CEO and President, succeeding Co-Founder Chris Gibson, Ph.D., who will become Chairman of the Board and interim Executive Advisor. The move, unanimously approved by the

Keros Therapeutics Reports Third Quarter 2025 Financial Results

Keros Therapeutics Reports Third Quarter 2025 Financial Results

✨ Onyx Summary Keros Therapeutics reported a third-quarter 2025 net loss of $7.3 million, significantly reduced from $53.0 million a year earlier, driven by revenue from its licensing agreement with Takeda. The company ended the quarter with $693.5 million in cash and plans to return $375 million to

Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update

Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update

✨ Onyx Summary Foghorn Therapeutics reported third-quarter 2025 collaboration revenue of $8.2 million and a net loss of $15.8 million, ending the quarter with $180.3 million in cash and a runway extending into 2028. The company advanced its oncology pipeline—including FHD-909 in Phase 1 with Lilly and

Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients

Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients

✨ Onyx Summary Guardant Health reported new real-world data showing a 95% adherence rate for its FDA-approved Shield blood-based colorectal cancer screening test, significantly higher than traditional colonoscopy or stool-based methods. Additional findings from clinics in Appalachia showed Shield increased overall screening rates from 45% to 90%, reinforcing its role in